94 related articles for article (PubMed ID: 25484390)
21. Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib.
Iacovelli R; Mancini ML; Risi E; Palazzo A; Cortesi E
Int J Dermatol; 2012 Feb; 51(2):221-2. PubMed ID: 22250635
[TBL] [Abstract][Full Text] [Related]
22. [Management of side effects of targeted therapies in renal cancer: cutaneous side effects].
Robert C; Gimel P
Bull Cancer; 2011; 98(3 Suppl):S35-46. PubMed ID: 25819125
[TBL] [Abstract][Full Text] [Related]
23. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.
Yang CH; Chuang CK; Hsieh JJ; Chang JW
Expert Opin Drug Saf; 2010 May; 9(3):459-70. PubMed ID: 20113155
[TBL] [Abstract][Full Text] [Related]
26. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Diamantis ML; Chon SY
J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
[TBL] [Abstract][Full Text] [Related]
28. Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.
Czarnecka AM; Oborska S; Rzepecki P; Szczylik C
Future Oncol; 2015; 11(1):17-26. PubMed ID: 24953672
[TBL] [Abstract][Full Text] [Related]
29. A Cross-Sectional Investigation of Fatigue, Mucositis, Hand-Foot Syndrome and Dysgeusia in Advanced Renal Cell Carcinoma Treatment: Final Results From the FAMOUS Study.
Goebell PJ; Müller L; Hurtz HJ; Koska M; Busies S; Marschner N
Clin Genitourin Cancer; 2016 Feb; 14(1):63-8. PubMed ID: 26520429
[TBL] [Abstract][Full Text] [Related]
30. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Wong MK; Jarkowski A
Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
[TBL] [Abstract][Full Text] [Related]
31. [Management of sunitinib-associated adverse events].
Kanda H; Masui S; Yamada Y; Arima K; Sugimura Y
Hinyokika Kiyo; 2012 Nov; 58(11):639-46. PubMed ID: 23254793
[TBL] [Abstract][Full Text] [Related]
32. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review.
Boehm S; Rothermundt C; Hess D; Joerger M
Gerontology; 2010; 56(3):303-9. PubMed ID: 19940466
[TBL] [Abstract][Full Text] [Related]
34. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
Bjarnason GA; Khalil B; Hudson JM; Williams R; Milot LM; Atri M; Kiss A; Burns PN
Urol Oncol; 2014 May; 32(4):480-7. PubMed ID: 24321258
[TBL] [Abstract][Full Text] [Related]
35. The Efficacy and Safety of the Shouzu Ning Decoction Treatment for Multi-Kinase Inhibitors-Associated Severe Hand-Foot Skin Reaction.
Shou L; Shao T; Zhao F; Chen S; Chen Q; Shu Q
Cancer Manag Res; 2021; 13():45-53. PubMed ID: 33442293
[TBL] [Abstract][Full Text] [Related]
36. Sunitinib in metastatic renal cell carcimoma: a single-center experience.
Krishna VM; Noronha V; Prabhash K; Joshi A; Patil V; Bhosale B; Ravi T; Menon H; Gupta S; Banavali SD; Bakshi G; Tangaonkar HB
Indian J Cancer; 2013; 50(3):268-73. PubMed ID: 24061470
[TBL] [Abstract][Full Text] [Related]
37. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
38. Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.
Zimmerman EI; Gibson AA; Hu S; Vasilyeva A; Orwick SJ; Du G; Mascara GP; Ong SS; Chen T; Vogel P; Inaba H; Maitland ML; Sparreboom A; Baker SD
Cancer Res; 2016 Jan; 76(1):117-26. PubMed ID: 26677977
[TBL] [Abstract][Full Text] [Related]
39. Toxic effects of multiple anticancer drugs on skin.
Kamil N; Kamil S; Ahmed SP; Ashraf R; Khurram M; Ali MO
Pak J Pharm Sci; 2010 Jan; 23(1):7-14. PubMed ID: 20067860
[TBL] [Abstract][Full Text] [Related]
40. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Yildiz I; Sen F; Basaran M; Ekenel M; Agaoglu F; Darendeliler E; Tunc HM; Ozcan F; Bavbek S
Jpn J Clin Oncol; 2011 Dec; 41(12):1380-7. PubMed ID: 22013228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
